Title: Vical to Present at American Society of Gene Therapy Annual
Meeting Date: 5/30/2007 8:00:00 AM
SEATTLE, May 30 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today
announced that the company will present updates on multiple research and development
projects over the course of the five-day annual meeting of the American Society of Gene
Therapy (Seattle, May 30 - June 3). Non-clinical data to be presented include:
* Analysis of Plasmid-Based Products: Development of a Novel Potency
Assay, May 30, by Alain Rolland, Pharm.D., Ph.D., Vical's Senior Vice
President of Product Development.
* Vaxfectin(TM)-formulated Plasmid DNA Measles Vaccine Elicits Protective
Immune Response in Non-Human Primates, May 31, by Adrian Vilalta, Ph.D.,
Vical's Senior Scientific Manager of Immunogen Discovery.
* Vaccination with Linear Expression Cassettes Protects Mice Against
Lethal Influenza A Challenge, June 2, by Adrian Vilalta, Ph.D., Vical's
Senior Scientific Manager of Immunogen Discovery.
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA
delivery technologies for the prevention and treatment of serious or life-threatening
diseases. Potential applications of the company's DNA delivery technology include DNA
vaccines for infectious diseases or cancer, in which the expressed protein is an
immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system
stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic
growth factor. The company is developing certain infectious disease vaccines and cancer
therapeutics internally. In addition, the company collaborates with major pharmaceutical
companies and biotechnology companies that give it access to complementary technologies or
greater resources. These strategic partnerships provide the company with mutually
beneficial opportunities to expand its product pipeline and address significant unmet
medical needs. Additional information on Vical is available at www.vical.com.
This press release contains forward-looking statements subject to risks and
uncertainties that could cause actual results to differ materially from those projected.
Forward-looking statements include statements about the company's focus, collaborative
partners, product candidates, and developmental status. Risks and uncertainties include
whether any product candidates will be shown to be safe and efficacious in clinical
trials, the timing of clinical trials, whether Vical or its collaborative partners will
seek or gain approval to market any product candidates, the dependence of the company on
its collaborative partners, and additional risks set forth in the company's filings with
the Securities and Exchange Commission. These forward-looking statements represent the
company's judgment as of the date of this release. The company disclaims, however, any
intent or obligation to update these forward-looking statements.
Contacts: Investors: Media:
Alan R. Engbring Susan Neath
Vical Incorporated Porter Novelli Life Sciences
(858) 646-1127 (619) 849-6007
Website: www.vical.com
SOURCE Vical Incorporated
-0- 05/30/2007
/CONTACT: Investors, Alan R. Engbring of Vical Incorporated,
+1-858-646-1127; Media, Susan Neath of Porter Novelli Life Sciences,
+1-619-849-6007/
/Web site: http://www.vical.com/
(VICL)
CO: Vical Incorporated; American Society of Gene Therapy
ST: Washington
IN: HEA MTC IDC
SU: SVY
AZ-WB
-- CLW003 --
6010 05/30/2007 08:00 EDT http://www.prnewswire.com
|